| Ytd | 15.69% | |
| 1y | -61.92% |
| Open | 4.06 | Prev Close | 4.09 | Low | 3.94 | High | 4.09 | Mkt Cap | 197.80M |
| Vol | 149.08K | Avg Vol | 963.36K | EPS | -0.39 | P/E | -10.58 | Forward P/E | -124.75 |
| Beta | 1.99 | Short Ratio | 7.78 | Inst. Own | 40.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 4.54 | 200-d Avg | 4.26 | 1yr Est | 12.00 |
LFMD News
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and specialty care today ann
LifeMD (NASDAQ:LFMD) affirms FY2026 sales outlook from $220.000 million-$230.000 million to $220.000
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.20) per share which beat the analyst consensus
Hims & Hers stock falls as Amazon launches a weight loss program with integrated care, pricing o
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced tha
Novo Nordisk launches the first Wegovy subscription program. Save on injections and pills through Ro
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the
https://www.sec.gov/Archives/edgar/data/948320/0001493152-26-011228-index.html
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the
Wall Street analysts upgraded PennyMac, LifeMD, Upstart, Circle Internet, and Rocket Companies. See
Mizuho analyst Steven Valiquette upgrades LifeMD (NASDAQ:LFMD) from Neutral to Outperform and rai
Freedom Capital Markets analyst Ilya Zubkov maintains LifeMD (NASDAQ:LFMD) with a Buy and raises
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and raises the
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.04) per share which beat the analyst consensus
Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the
Keybanc analyst Steve Dechert maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the pr
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Neutral and lowers the pri
Lake Street analyst Brooks O'Neil maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the pr
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers th
Here's a look at the details from LifeMD's Q3 earnings report.
LifeMD (NASDAQ:LFMD) lowers FY2025 sales outlook from $268.000 million-$275.000 million to $192.000
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.07) per share which missed the analyst consens
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prep
On Wednesday, 807 companies reached new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report